sanofi glp-1 FDA panel backs Sanofi's insulin/GLP-1 agonist combo Victoza tops Sanofi's Lyxumia in

Acta Neuropathol 134:537

If you take one of those, your A1c and glucose are worth tracking closely so your clinician can adjust the rest of your regimen

These studies suggest that despite the potential benefits of Lira, current evidence does not advocate the use of Lira in patients with NAFLD

Studies in animal models indicate that BPC-157 can enhance angiogenesis, promote wound healing, stimulate collagen synthesis, modulate the inflammatory response, and protect against oxidative stress

Entry of selective steroid receptor antagonists into different target tissues would be a new avenue to explore to avoid neurological side effects